Verteporfin photodynamic therapy for neovascular age-related ...

42 Results (1) – study cohortTABLE 8 Lesion characteristics for eligible eyes from independent grading of FA (column percentages withincharacteristic unless otherwise stated)Lesion characteristicNumber of eyes first treated> 350 days before the end of the studyNumber of eyes first treated≤ 350 days before the end of the studyTotalTotal eligible eyes (see Figure 3) 4919 1728 6647Eligible eyes with an independently 3182 (64.7%) 943 (54.6%) 4125 (62.1%)graded baseline angiogramLesion area, disc areas≤ 3 2225 (69.9%) 669 (70.9%) 2894 (70.2%)> 3 to ≤ 6 400 (12.6%) 140 (14.8%) 540 (13.1%)> 6 to ≤ 9 94 (3.0%) 33 (3.5%) 127 (3.1%)> 9 54 (1.7%) 18 (1.9%) 72 (1.7%)Missing or could not be graded 409 (12.9%) 83 (8.8%) 492 (11.9%)Greatest linear dimension, disc area≤ 3 1892 (59.5%) 549 (58.2%) 2441 (59.2%)> 3 to ≤ 6 966 (30.4%) 310 (32.9%) 1276 (30.9%)> 6 to ≤ 9 90 (2.8%) 26 (2.8%) 116 (2.8%)> 9 9 (0.3%) 4 (0.4%) 13 (0.3%)Missing or could not be graded 225 (7.1%) 54 (5.7%) 279 (6.8%)Lesion area composed of CNV0% 1 (0.0%) 0 (0.0%) 1 (0.0%)> 0% and < 50% 355 (11.2%) 121 (12.8%) 476 (11.5%)≥ 50% and < 100% 1305 (41.0%) 377 (40.0%) 1682 (40.8%)100% 1031 (32.4%) 352 (37.3%) 1383 (33.5%)Missing or could not be graded 490 (15.4%) 93 (9.9%) 583 (14.1%)CNV locationExtrafoveal 297 (9.3%) 99 (10.5%) 396 (9.6%)Juxtafoveal 408 (12.8%) 94 (10.0%) 502 (12.2%)Subfoveal 2051 (64.5%) 660 (70.0%) 2711 (65.7%)Missing or could not be graded 426 (13.4%) 90 (9.5%) 516 (12.5%)Lesion area composed of classic CNV≥ 50% to < 100% 1943 (61.1%) 585 (62.0%) 2528 (61.3%)> 0% to < 50% 588 (18.5%) 200 (21.2%) 788 (19.1%)0% 246 (7.7%) 75 (8.0%) 321 (7.8%)Missing or could not be graded 405 (12.7%) 83 (8.8%) 488 (11.8%)Evidence of occult CNV≥ 50% 402 (12.6%) 142 (15.1%) 544 (13.2%)> 0 and < 50% 128 (4.0%) 22 (2.3%) 150 (3.6%)0% 2243 (70.5%) 696 (73.8%) 2939 (71.2%)Missing or could not be graded 409 (12.9%) 83 (8.8%) 492 (11.9%)